Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Reviews in Endocrine and Metabolic Disorders
Published in: Reviews in Endocrine and Metabolic Disorders 3/2021

01-09-2021 | Echocardiography

Update in carcinoid heart disease - the heart of the matter

Authors: Kira Oleinikov, Amit Korach, David Planer, Dan Gilon, Simona Grozinsky-Glasberg

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 3/2021

Login to get access

Abstract

Carcinoid heart disease (CHD) is a paraneoplastic cardiac manifestation occurring in patients with carcinoid syndrome (CS) and advanced neuroendocrine malignancy. In about 20–40% of patients with CS, chronic exposure to tumor-released circulating vasoactive peptides typically results in right-sided valvular fibrosis leading to valve dysfunction and right heart failure. CHD remains a significant cause of morbidity and mortality. The management of patients with CHD is complex, as both the systemic malignant disease and the heart involvement have to be addressed. Early diagnosis and timely surgical intervention in selected patients are of utmost importance and offer a survival benefit. In patients with advanced carcinoid heart disease, valve replacement surgery is the most effective option to alleviate cardiac symptoms and contribute to survival outcomes. A collaboration of a multidisciplinary team in centers with experience is required to provide optimal patient management. Here, we review the current literature regarding CHD presentation, pathophysiology, diagnostic tools, and available treatment strategies.
Literature
1.
2.
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.CrossRefPubMedPubMedCentral
3.
Lloyd RV, Osamura RY, Klöppel G, Rosai J. WHO classification of Tumours of endocrine organs. 4th ed. Lyon: International Agency for Research on Cancer; 2017.
4.
Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18(4):525–34.PubMedPubMedCentralCrossRef
5.
Fanciulli G, Ruggeri RM, Grossrubatscher E, Calzo FL, Wood TD, Faggiano A, et al. Colao a; NIKE. Serotonin pathway in carcinoid syndrome: clinical, diagnostic, prognostic and therapeutic implications. Rev Endocr Metab Disord. 2020;21(4):599–612.PubMedCrossRef
6.
Boutzios G, Kaltsas G. Clinical syndromes related to gastrointestinal neuroendocrine neoplasms. Front Horm Res. 2015;44:40–57.PubMedCrossRef
7.
Møller JE, Connolly HM, Rubin J, Seward JB, Modesto K, Pellikka PA. Factors associated with progression of carcinoid heart disease. N Engl J Med. 2003;348(11):1005–15.PubMedCrossRef
8.
Lundin L, Norheim I, Landelius J, Oberg K, Theodorsson-Norheim E. Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation. 1988;77(2):264–9.PubMedCrossRef
9.
Dobson R, Burgess MI, Valle JW, Pritchard DM, Vora J, Wong C, et al. Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality. Br J Cancer. 2014;111(9):1703–9.PubMedPubMedCentralCrossRef
10.
Connolly HM, Schaff HV, Abel MD, Rubin J, Askew JW, Li Z, et al. Early and late outcomes of surgical treatment in carcinoid heart disease. J Am Coll Cardiol. 2015;66(20):2189–96.PubMedCrossRef
11.
Davar J, Connolly HM, Caplin ME, Pavel M, Zacks J, Bhattacharyya S, et al. Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement. J Am Coll Cardiol. 2017;69(10):1288–304.PubMedCrossRef
12.
Bhattacharyya S, Toumpanakis C, Burke M, Taylor AM, Caplin ME, Davar J. Features of carcinoid heart disease identified by 2-and 3-dimensional echocardiography and cardiac MRI. Circul: Cardiovasc Imaging. 2010;3(1):103–11.
13.
Simula DV, Edwards WD, Tazelaar HD, Connolly HM, Schaff HV. Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years. Mayo Clin Proc. 2002;77(2):139–47.PubMedCrossRef
14.
Ayme-Dietrich E, Aubertin-Kirch G, Maroteaux L, Monassier L. Cardiovascular remodeling and the peripheral serotonergic system. Arch Cardiovasc Dis. 2017;110(1):51–9.PubMedCrossRef
15.
Chen C, Han X, Fan F, Liu Y, Wang T, Wang J, et al. Serotonin drives the activation of pulmonary artery adventitial fibroblasts and TGF-β1/Smad3-mediated fibrotic responses through 5-HT 2A receptors. Mol Cell Biochem. 2014;397(1–2):267–76.PubMedCrossRef
16.
Grozinsky-Glasberg S, Grossman AB, Gross DJ. Carcinoid heart disease: from pathophysiology to treatment-‘something in the way it moves. Neuroendocrinology. 2015;101(4):263–73.PubMedCrossRef
17.
Goldberg E, Grau JB, Fortier JH, Salvati E, Levy RJ, Ferrari G. Serotonin and catecholamines in the development and progression of heart valve diseases. Cardiovasc Res. 2017;113(8):849–57.PubMedPubMedCentralCrossRef
18.
19.
Ayme-Dietrich E, Lawson R, Da-Silva S, Mazzucotelli JP, Monassier L. Serotonin contribution to cardiac valve degeneration: new insights for novel therapies? Pharmacol Res. 2019;140:33–42.PubMedCrossRef
20.
Yabanoglu S, Akkiki M, Seguelas MH, Mialet-Perez J, Parini A, Pizzinat N. Platelet derived serotonin drives the activation of rat cardiac fibroblasts by 5-HT2A receptors. J Mol Cell Cardiol. 2009;46(4):518–25.PubMedCrossRef
21.
Driesbaugh KH, Branchetti E, Grau JB, Keeney SJ, Glass K, Oyama MA, et al. Serotonin receptor 2B signaling with interstitial cell activation and leaflet remodeling in degenerative mitral regurgitation. J Mol Cell Cardiol. 2018;115:94–103.PubMedCrossRef
22.
Bhattacharyya S, Raja SG, Toumpanakis C, Caplin ME, Dreyfus GD, Davar J. Outcomes, risks and complications of cardiac surgery for carcinoid heart disease. Eur J Cardiothorac Surg. 2011;40(1):168–72.PubMedCrossRef
23.
Castillo J, Silvay G, Weiner M. Anesthetic management of patients with carcinoid syndrome and carcinoid heart disease: the Mount Sinai algorithm. J Cardiothorac Vasc Anesth. 2018;32(2):1023–31.PubMedCrossRef
24.
Bhattacharyya S, Toumpanakis C, Chilkunda D, Caplin ME, Davar J. Risk factors for the development and progression of carcinoid heart disease. Am J Cardiol. 2011;107(8):1221–6.PubMedCrossRef
25.
Dobson R, Burgess MI, Pritchard DM, Cuthbertson DJ. The clinical presentation and management of carcinoid heart disease. Int J Cardiol. 2014;173(1):29–32.PubMedCrossRef
26.
Bhattacharyya S, Toumpanakis C, Caplin ME, Davar J. Analysis of 150 patients with carcinoid syndrome seen in a single year at one institution in the first decade of the twenty-first century. Am J Cardiol. 2008;101(3):378–81.PubMedCrossRef
27.
Dobson R, Valle JW, Burgess MI, Poston GJ, Cuthbertson DJ. Variation in cardiac screening and Management of Carcinoid Heart Disease in the UK and Republic of Ireland. Clin Oncol. 2015;27(12):741–6.CrossRef
28.
Dobson R, Burgess MI, Banks M, Pritchard DM, Vora J, Valle JW, et al. The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study. PLoS One. 2013;8(9):e73679.PubMedPubMedCentralCrossRef
29.
Zuetenhorst JM, Korse CM, Bonfrer JM, Bakker RH, Taal BG. Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease. Br J Cancer. 2004;90(11):2073–9.PubMedPubMedCentralCrossRef
30.
Bhattacharyya S, Toumpanakis C, Caplin ME, Davar J. Usefulness of N-terminal pro–brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. Am J Cardiol. 2008;102(7):938–42.PubMedCrossRef
31.
Korse CM, Taal BG, de Groot CA, Bakker RH, Bonfrer JM. Chromogranin-a and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor. J Clin Oncol. 2009;27(26):4293–9.PubMedCrossRef
32.
33.
Zuetenhorst JM, Bonfrer JM, Korse CM, Bakker R, van Tinteren H, Taal BG. Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor. Cancer. 2003;97(7):1609–15.PubMedCrossRef
34.
Bergestuen DS, Edvardsen T, Aakhus S, Ueland T, Oie E, Vatn M, et al. Activin a in carcinoid heart disease: a possible role in diagnosis and pathogenesis. Neuroendocrinology. 2010;92(3):168–77.PubMedCrossRef
35.
Zahid W, Bergestuen D, Haugaa KH, Ueland T, Thiis-Evensen E, Aukrust P, et al. Myocardial function by two-dimensional speckle tracking echocardiography and Activin a May predict mortality in patients with carcinoid intestinal disease. Cardiology. 2015;132(2):81–90.PubMedCrossRef
36.
Agha AM, Lopez-Mattei J, Donisan T, Balanescu D, Iliescu CA, Banchs J, et al. Multimodality imaging in carcinoid heart disease. Open Heart. 2019;6(1):e001060.PubMedPubMedCentralCrossRef
37.
Edwards NC, Yuan M, Nolan O, Pawade TA, Oelofse T, Singh H, et al. Effect of Valvular surgery in carcinoid heart disease: an observational cohort study. J Clin Endocrinol Metab. 2016;101(1):183–90.PubMedCrossRef
38.
Nguyen A, Schaff HV, Abel MD, Luis SA, Lahr BD, Halfdanarson TR, et al. Improving outcome of valve replacement for carcinoid heart disease. J Thorac Cardiovasc Surg. 2019;158(1):99–107.PubMedCrossRef
39.
Mokhles P, van Herwerden LA, de Jong PL, de Herder WW, Siregar S, Constantinescu AA, et al. Carcinoid heart disease: outcomes after surgical valve replacement. Eur J Cardiothorac Surg. 2012;41(6):1278–83.PubMedCrossRef
40.
Haugaa KH, Bergestuen DS, Sahakyan LG, Skulstad H, Aakhus S, Thiis-Evensen E, et al. Evaluation of right ventricular dysfunction by myocardial strain echocardiography in patients with intestinal carcinoid disease. J Am Soc Echocardiogr. 2011;24(6):644–50.PubMedCrossRef
41.
Dobson R, Cuthbertson DJ, Burgess MI. The optimal use of cardiac imaging in the quantification of carcinoid heart disease. Endocr Relat Cancer. 2013;20(5):R247–55.PubMedCrossRef
42.
Castillo JG, Naib T, Zacks JS, Adams DH. Echocardiography in functional midgut neuroendocrine tumors: when and how often. Rev Endocrine Metab Disorders. 2017;18(4):411–21.CrossRef
43.
44.
Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27(28):4656–63.PubMedCrossRef
45.
Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–33.PubMedCrossRef
46.
Hofland J, Herrera-Martínez AD, Zandee WT, de Herder WW. Management of carcinoid syndrome: a systematic review and meta-analysis. Endocr Relat Cancer. 2019;26(3):R145–56.PubMedCrossRef
47.
Woltering EA, Wright AE, Stevens MA, Wang YZ, Boudreaux JP, Mamikunian G, et al. Development of effective prophylaxis against intraoperative carcinoid crisis. J Clin Anesth. 2016;32:189–93.PubMedCrossRef
48.
Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol. 2017;35(1):14–23.PubMedCrossRef
49.
Pavel M, Gross DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RR, et al. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. Endocr Relat Cancer. 2018;25(3):309–22.PubMedPubMedCentralCrossRef
50.
Anthony LB, Kulke MH, Caplin ME, Bergsland E, Öberg K, Pavel M, et al. Long-term safety experience with Telotristat ethyl across five clinical studies in patients with carcinoid syndrome. Oncologist. 2019;24(8):e662–70.PubMedPubMedCentralCrossRef
51.
Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005–12.PubMedCrossRef
52.
Oberg K. Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion. 2000;62:92–7.PubMedCrossRef
53.
Pavel ME, Baum U, Hahn EG, Schuppan D, Lohmann T. Efficacy and tolerability of pegylated IFN-α in patients with neuroendocrine gastroenteropancreatic carcinomas. J Interf Cytokine Res. 2006;26(1):8–13.CrossRef
54.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35.PubMedPubMedCentralCrossRef
55.
Davis LM, Nicou N, Martin W, Corcoran B, Mulholland N, Srirajaskanthan R, et al. Timing of peptide receptor radiotargeted therapy in relation to cardiac valve surgery for carcinoid heart disease in patients with neuroendocrine metastases and cardiac syndrome. A single-Centre study from a Centre of excellence. Nucl Med Commun. 2020;41(6):575–81.PubMedCrossRef
56.
Foster DS, Jensen R, Norton JA. Management of liver neuroendocrine tumors in 2018. Jama Oncol. 2018;4(11):1605–6.PubMedCrossRef
57.
Kennedy A, Bester L, Salem R, Sharma RA, Parks RW, Ruszniewski P. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-liver-metastases consensus conference. HPB. 2015;17(1):29–37.PubMedCrossRef
58.
Bernheim AM, Connolly HM, Rubin J, Møller JE, Scott CG, Nagorney DM, et al. Role of hepatic resection for patients with carcinoid heart disease. Mayo Clin Proc. 2008;83(2):143–50.PubMedCrossRef
59.
Eriksson J, Stålberg P, Nilsson A, Krause J, Lundberg C, Skogseid B, et al. Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg. 2008;32(5):930–8.PubMedCrossRef
60.
Korach A, Grozinsky-Glasberg S, Atlan J, Dabah A, Atlan K, Rudis E, et al. Valve replacement in patients with carcinoid heart disease: choosing the right valve at the right time. J Heart Valve Dis. 2016;25(3):349–55.PubMed
61.
Komoda S, Komoda T, Pavel ME, Morawietz L, Wiedenmann B, Hetzer R, et al. Cardiac surgery for carcinoid heart disease in 12 cases. Gen Thorac Cardiovasc Surg. 2011;59(12):780–5.PubMedCrossRef
62.
Castillo JG, Filsoufi F, Rahmanian PB, Anyanwu A, Zacks JS, Warner RR, et al. Early and late results of valvular surgery for carcinoid heart disease. J Am Coll Cardiol. 2008;51(15):1507–9.PubMedCrossRef
63.
Kuntze T, Owais T, Secknus MA, Kaemmerer D, Baum R, Girdauskas E. Results of contemporary valve surgery in patients with carcinoid heart disease. J Heart Valve Dis. 2016;1:356–63.
64.
Mujtaba SS, Clark S. Carcinoid heart disease: early outcomes after surgical valve replacement in nine patients. Heart Surg Forum. 2018;21(1):E040–3.PubMedCrossRef
65.
Yong MS, Kong G, Ludhani P, Michael M, Morgan J, Hofman MS, et al. Early outcomes of surgery for carcinoid heart disease. Heart, Lung Circul. 2020;29(5):742–7.CrossRef
66.
Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Fleisher LA, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2017;70(2):252–89.PubMedCrossRef
67.
Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739–91.PubMedCrossRef
68.
Kaltsas G, Caplin M, Davies P, Ferone D, Garcia-Carbonero R, Grozinsky-Glasberg S, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pre-and perioperative therapy in patients with neuroendocrine tumors. Neuroendocrinology. 2017;105(3):245–54.PubMedCrossRef
69.
Silaschi M, Barr J, Chaubey S, Nicou N, Srirajaskanthan R, Byrne J, et al. Optimized outcomes using a standardized approach for the treatment of patients with carcinoid heart disease. Neuroendocrinology. 2017;104(3):257–63.PubMedCrossRef
70.
Luthra S, Olevano C, Richens T, Tsang GM. Percutaneous transcatheter valve-in-valve pulmonary and tricuspid replacement in carcinoid heart disease. JACC: Case Reports. 2020;2(4):533–6.PubMedPubMedCentral
Metadata
Title
Update in carcinoid heart disease - the heart of the matter
Authors
Kira Oleinikov
Amit Korach
David Planer
Dan Gilon
Simona Grozinsky-Glasberg
Publication date
01-09-2021
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 3/2021
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-020-09624-y

Other articles of this Issue 3/2021

Reviews in Endocrine and Metabolic Disorders 3/2021 Go to the issue

ReviewPaper

PRRT: identikit of the perfect patient

ReviewPaper

Imaging of neuroendocrine tumors: A pictorial review of the clinical value of different imaging modalities

ReviewPaper

Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer

ReviewPaper

Classification of neuroendocrine neoplasms: lights and shadows

ReviewPaper

Evaluating cost-effectiveness in the management of neuroendocrine neoplasms

ReviewPaper

Are recist criteria adequate in assessing the response to therapy in metastatic NEN?
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits